ABSTRACT
Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, WilcoxFogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF. (Herbert Irving Comprehensive Cancer Center and the Departments of Pathology and Cell Biology and Medicine, Columbia University, New York, USA; Institute for Stem Cell Biology and Regenerative Medicine and the Departments of Pathology and Medicine, Division of Oncology, Stanford University, Stanford, and the Departments of Pediatrics and Computer Science and Engineering, University of California San Diego, San Diego, California, USA; Faculty of Engineering, BarIlan University, Ramat Gan, Israel; the National Surgical Adjuvant Breast and Bowel Project, NRG Oncology and the Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, USA; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea; Department of Biochemistry and Molecular Biology, Medical School of Henan University, Kaifeng, China.) CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 2016;374:211–22.